FLORBETABEN F-18 - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for florbetaben f-18 and what is the scope of patent protection?

Florbetaben f-18 is the generic ingredient in one branded drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Florbetaben f-18 has thirty-five patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for FLORBETABEN F-18

International Patents:	35
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	24
Patent Applications:	239
DailyMed Link:	FLORBETABEN F-18 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FLORBETABEN F-18

Generic Entry Date for FLORBETABEN F-18^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FLORBETABEN F-18

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Pennsylvania	Phase 3
National Institutes of Health (NIH)	Phase 3
Life Molecular Imaging GmbH	Phase 3

See all FLORBETABEN F-18 clinical trials

Pharmacology for FLORBETABEN F-18

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Positron Emitting Activity

US Patents and Regulatory Information for FLORBETABEN F-18

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Life Molecular	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for FLORBETABEN F-18

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Denmark	2213652		⤷ Sign Up
Poland	2213652		⤷ Sign Up
South Africa	200705104	Stilbene derivatives and their use for binding and imaging amyloid plaques	⤷ Sign Up
South Korea	20070093427	STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES	⤷ Sign Up
South Korea	101321619		⤷ Sign Up
Japan	5128956		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for FLORBETABEN F-18

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2213652	8/2015	Austria	⤷ Sign Up	PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224
2213652	132015902339134	Italy	⤷ Sign Up	PRODUCT NAME: FLORBETABEN (18)(NEURACEQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/906, 20140224
2213652	SPC/GB15/010	United Kingdom	⤷ Sign Up	PRODUCT NAME: FLORBETABEN (18F), WHICH IS (4-((E)-2-(4-(2-(2-(2-(1F)FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETHENYL)-N-METHYLANILINE); REGISTERED: UK EU/1/13/906/001 20140224
2213652	PA2015005	Lithuania	⤷ Sign Up	PRODUCT NAME: FLORBETABENUM (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
2213652	C02213652/01	Switzerland	⤷ Sign Up	PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66210 23.08.2017
2213652	122015000018	Germany	⤷ Sign Up	PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for FLORBETABEN F-18

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FLORBETABEN F-18

Recent Clinical Trials for FLORBETABEN F-18

Pharmacology for FLORBETABEN F-18

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FLORBETABEN F-18